Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients

Anna Solini, Vittorio Simeon, Lisa Derosa, Paola Orlandi, Chiara Rossi, Andrea Fontana, Luca Galli, Teresa Di Desidero, Anna Fioravanti, Sara Lucchesi, Luigi Coltelli, Laura Ginocchi, Giacomo Allegrini, Romano Danesi, Alfredo Falcone, Guido Bocci

Research output: Contribution to journalArticlepeer-review


VEGFR-2 and P2X7 receptor (P2X7R) have been described to stimulate the angiogenesis and inflammatory processes of prostate cancer. The present study has been performed to investigate the genetic interactions among VEGFR-2 and P2X7R SNPs and their correlation with overall survival (OS) in a population of metastatic prostate cancer patients. Analyses were performed on germline DNA obtained from blood samples and SNPs were investigated by real-time PCR technique. The survival dimensionality reduction (SDR) methodology was applied to investigate the genetic interaction between SNPs. One hundred patients were enrolled. The SDR software provided two genetic interaction profiles consisting of the combination between specific VEGFR-2 (rs2071559, rs11133360) and P2X7R (rs3751143, rs208294) genotypes. The median OS was 126 months (95% CI, 115.94-152.96) and 65.65 months (95% CI, 52.95-76.53) for the favorable and the unfavorable genetic profile, respectively (p <0.0001). The genetic statistical interaction between VEGFR-2 (rs2071559, rs11133360) and P2X7R (rs3751143, rs208294) genotypes may identify a population of prostate cancer patients with a better prognosis.

Original languageEnglish
Pages (from-to)28743-28754
Number of pages12
Issue number30
Publication statusPublished - 2015


  • P2X7 receptor
  • Polymorphisms
  • Prostate cancer
  • Survival dimensionality reduction analysis
  • VEGFR-2

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Genetic interaction of P2X<sub>7</sub> receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients'. Together they form a unique fingerprint.

Cite this